CD4 and cancer: Mean ± SEM percentageof T cells with CD4+CD25+FOXP3+Helios+ phenotypewere 15.59 ± 4.6%, 12.63 ± 3.6%, and 5.90 ± 2.6% inthe presence of cancer-ASCs and normal-ASCs and inthe control group, respectively.